pharmasset is on a roll offers 100% cure rate, page-7

From Michelle Miller CEO of Biotron, with her kind permission to share with other shareholders.



Pharmasset is a company with which we are very familiar, and it has interesting antiviral programs.  Certainly Wall St has been very supportive of this particular stock.

It is developing HCV drugs that are of a different class to BIT225.  Potentially our drug could be synergistic (i.e. work well in combination) with theirs.  We do not see it as a competitor to Biotron, as there is the potential to combine drugs of that class, as well as another, along with BIT225 to make a cocktail of direct-acting drugs to treat HCV.  

It is also worth noting that drugs of the class that Pharmasset is targeting tend to have a high rate of generation of resistance i.e. the drugs can rapidly become ineffective.  To date, that has not been our experience with BIT225, which is to be expected due to its mode of action.  

And while the Pharmasset drug is good, there are a number of excellent candidates of that particular class of drug in development by other companies, so it will have competition.  

The Pharmasset drugs do not target HIV.  We are sitting in a unique position with a drug that targets both these viruses.

I hope that this addresses your queries.  Thank you for your support of Biotron.